Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
RNAZ Transcode Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: RNAZ
Price (delayed)
$9.25
Market cap
$7.71M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$808.39M
Enterprise value
-$3.86M
Highlights
The quick ratio has soared by 160% YoY and by 126% from the previous quarter
Transcode Therapeutics's equity has soared by 125% YoY
The EPS has shrunk by 72% QoQ and by 32% YoY
Transcode Therapeutics's net income has plunged by 52% from the previous quarter and by 50% YoY
Key stats
What are the main financial stats of RNAZ
Market
Valuations
Earnings
Shares outstanding
833,619
Market cap
$7.71M
Enterprise value
-$3.86M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.02
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$15.54M
Net income
-$25.51M
EBIT
-$25.5M
EBITDA
-$25.05M
Free cash flow
-$12.51M
Per share
Balance sheet
Liquidity
EPS
-$808.39M
EPS diluted
-$808.39M
Free cash flow per share
-$72.64
Book value per share
$550.82
Revenue per share
$0
TBVPS
$76.6
Total assets
$13.19M
Total liabilities
$2.9M
Debt
$0
Equity
$10.29M
Working capital
$10.53M
Debt to equity
0
Current ratio
5.2
Quick ratio
4.74
Net debt/EBITDA
0.46
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-349.3%
Return on equity
-908.4%
Return on invested capital
N/A
Return on capital employed
-238.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RNAZ stock price
How has the Transcode Therapeutics stock price performed over time
Intraday
14.91%
1 week
23.33%
1 month
29.55%
1 year
-98.55%
YTD
-90.2%
QTD
18.59%
Financial performance
How have Transcode Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$15.54M
Net income
-$25.51M
Gross margin
N/A
Net margin
N/A
Transcode Therapeutics's net income has plunged by 52% from the previous quarter and by 50% YoY
The company's operating income rose by 13% YoY
Price vs fundamentals
How does RNAZ's price correlate with its fundamentals
Growth
What is Transcode Therapeutics's growth rate over time
Valuation
What is Transcode Therapeutics stock price valuation
P/E
N/A
P/B
0.02
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has shrunk by 72% QoQ and by 32% YoY
Transcode Therapeutics's equity has soared by 125% YoY
Efficiency
How efficient is Transcode Therapeutics business performance
The company's return on equity has shrunk by 70% YoY but it rose by 25% QoQ
The company's return on assets fell by 46% YoY and by 21% QoQ
Dividends
What is RNAZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RNAZ.
Financial health
How did Transcode Therapeutics financials performed over time
The quick ratio has soared by 160% YoY and by 126% from the previous quarter
The current ratio has soared by 110% YoY and by 103% from the previous quarter
Transcode Therapeutics's debt is 100% less than its equity
Transcode Therapeutics's equity has soared by 125% YoY
Transcode Therapeutics's debt has plunged by 100% from the previous quarter and by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.